These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34111175)

  • 1. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells.
    Kato T; Ono H; Fujii M; Akahoshi K; Ogura T; Ogawa K; Ban D; Kudo A; Tanaka S; Tanabe M
    PLoS One; 2021; 16(6):e0252917. PubMed ID: 34111175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.
    Li B; Xing F; Wang J; Wang X; Zhou C; Fan G; Zhuo Q; Ji S; Yu X; Xu X; Qin Y; Li Z
    Cancer Lett; 2024 Oct; 602():217197. PubMed ID: 39216548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
    Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
    Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
    Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.
    Chen S; Wang Y; Zhang WL; Dong MS; Zhang JH
    Mol Med Rep; 2017 Apr; 15(4):1461-1470. PubMed ID: 28259943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
    Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer.
    Lin X; Tan Y; Pan L; Tian Z; Lin L; Su M; Ou G; Chen Y
    Cancer Chemother Pharmacol; 2024 Mar; 93(3):237-251. PubMed ID: 38040978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
    Uehara M; Domoto T; Takenaka S; Bolidong D; Takeuchi O; Miyashita T; Minamoto T
    Cancer Sci; 2020 Dec; 111(12):4405-4416. PubMed ID: 32986894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
    Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
    Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer.
    Ono H; Murase Y; Yamashita H; Kato T; Asano D; Ishikawa Y; Watanabe S; Ueda H; Akahoshi K; Ogawa K; Kudo A; Akiyama Y; Tanaka S; Tanabe M
    Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36866763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
    Zhang X; Jin FS; Zhang LG; Chen RX; Zhao JH; Wang YN; Wang EF; Jiang ZD
    Asian Pac J Cancer Prev; 2013; 14(7):4261-5. PubMed ID: 23991987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer.
    Kutschat AP; Hamdan FH; Wang X; Wixom AQ; Najafova Z; Gibhardt CS; Kopp W; Gaedcke J; Ströbel P; Ellenrieder V; Bogeski I; Hessmann E; Johnsen SA
    Cancer Res; 2021 Jun; 81(11):2943-2955. PubMed ID: 33436389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
    Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
    Zhou J; Chen Z; Malysa A; Li X; Oliveira P; Zhang Y; Bepler G
    PLoS One; 2013; 8(3):e58091. PubMed ID: 23483975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis.
    Han QL; Zhou YH; Lyu Y; Yan H; Dai GH
    J Clin Pharm Ther; 2018 Apr; 43(2):163-169. PubMed ID: 29214667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
    Akita H; Zheng Z; Takeda Y; Kim C; Kittaka N; Kobayashi S; Marubashi S; Takemasa I; Nagano H; Dono K; Nakamori S; Monden M; Mori M; Doki Y; Bepler G
    Oncogene; 2009 Aug; 28(32):2903-9. PubMed ID: 19543324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
    Gao Z; Han B; Shen J; Gu A; Zhong H
    Zhongguo Fei Ai Za Zhi; 2011 Apr; 14(4):340-4. PubMed ID: 21496433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.